



Acknowledgements

Table of Contents

List of Abbreviations

| | | |
|-----------------|--|-----------|
| 1. | Introduction | 1 |
| 1.1. | Classification of Poorly Soluble Drugs | 2 |
| 1.1.1. | <i>The Biopharmaceutics Classification Scheme (BCS)</i> | 2 |
| 1.1.2. | <i>The Biopharmaceutics Drug Disposition Classification Scheme (BDDCS)</i> | 3 |
| 1.2. | Intraluminal Events in the Context of Oral Absorption and Factors that Limit the Bioavailability of Orally Administered Drugs | 4 |
| 1.2.1. | <i>Solubility, Dissolution, and Precipitation</i> | 6 |
| 1.2.2. | <i>Complexation, Degradation</i> | 9 |
| 1.2.3. | <i>Permeability Considerations</i> | 9 |
| 1.2.4. | <i>Site-Specific Absorption</i> | 10 |
| 1.2.5. | <i>Exotransport</i> | 10 |
| 1.2.6. | <i>First Pass Metabolism</i> | 10 |
| 1.3. | Current Methods for Predicting the Permeability of Drugs | 11 |
| 1.3.1. | <i>Jejunal Perfusion Experiments</i> | 11 |
| 1.3.2. | <i>In Vitro Techniques for Predicting the Intestinal Permeability of a Drug</i> | 12 |
| 1.3.2.1. | <i>Parallel Artificial Membrane Permeability Assay (PAMPA)</i> | 12 |
| 1.3.2.2. | <i>Surface Activity Profiling (SAP)</i> | 12 |
| 1.3.2.3. | <i>Estimation Using Physicochemical Drug Properties</i> | 13 |
| 1.3.2.4. | <i>Caco 2 Cell Assay</i> | 13 |
| 1.3.2.5. | <i>HT-29 Cell Assay</i> | 14 |
| 1.3.2.6. | <i>MDCK II Cell Assay</i> | 14 |
| 1.3.2.7. | <i>LLC-PK1 Cell Assay</i> | 14 |



| | | |
|---------------|---|-----------|
| 1.4. | Current Methods for Predicting the Release Characteristics of Drug Products | 15 |
| 1.4.1. | <i>Compendial Dissolution Methods</i> | 15 |
| 1.4.1.1. | <i>Compendial Dissolution Media</i> | 15 |
| 1.4.1.2. | <i>Compendial Dissolution Apparatus</i> | 16 |
| 1.4.2. | <i>Biorelevant Dissolution Testing</i> | 17 |
| 1.5. | Mathematical Description of Dissolution and Release | 22 |
| 1.5.1. | <i>Fick's Diffusion Law and Noyes-Whitney Kinetics</i> | 22 |
| 1.5.2. | <i>Zero Order Dissolution Kinetics</i> | 23 |
| 1.5.3. | <i>First Order Dissolution Kinetics</i> | 24 |
| 1.5.4. | <i>Weibull Distribution</i> | 25 |
| 1.5.5. | <i>Higuchi Model</i> | 26 |
| 1.5.6. | <i>Korsmeyer-Peppas Kinetics</i> | 27 |
| 1.5.7. | <i>Dissolution Kinetics in Swellable, Erodible Matrices</i> | 28 |
| 1.6. | Effect of Food on Drug Absorption | 28 |
| 1.6.1. | <i>Physiological Changes in Response to Meal Ingestion</i> | 28 |
| 1.6.2. | <i>Possible Effects of Food on the Performance of a Drug or Drug Formulation</i> | 30 |
| 1.6.2.1. | <i>Gastric Conditions</i> | 30 |
| 1.6.2.2. | <i>Small Intestinal Conditions</i> | 31 |
| 1.6.2.3. | <i>Further Considerations for Food Effects</i> | 31 |
| 1.6.3. | <i>Prediction of Food Effects</i> | 32 |
| 1.6.3.1. | <i>BCS-Based Predictions</i> | 32 |
| 1.6.3.2. | <i>Dissolution Studies</i> | 33 |
| 1.6.3.3. | <i>Preclinical Studies</i> | 33 |
| 1.6.3.4. | <i>Combining Laboratory and Pharmacokinetic Data</i> | 33 |
| 1.7. | Physiologically Based Pharmacokinetic (PBPK) Modeling | 33 |
| 1.8. | Aim of the Thesis and Issues Addressed in this Work | 40 |



| | | |
|-----------------|---|------------|
| 2. | Results and Discussion | 41 |
| 2.1. | Combining Dissolution Testing and PBPK Modeling for Establishing <i>in Vitro</i> – <i>in Silico</i> – <i>in Vivo</i> Correlations (IVISIVC) – Advantages and Limitations | 41 |
| 2.1.1. | <i>Establishing IVISIVC – Neutral Drugs</i> | 44 |
| 2.1.2. | <i>Establishing IVISIVC – Weakly Acidic Drugs</i> | 46 |
| 2.1.3. | <i>Establishing IVISIVC – Weakly Basic Drugs</i> | 56 |
| 2.1.3.1. | <i>Theoretical Models for Simulating Drug Precipitation</i> | 57 |
| 2.1.3.2. | <i>In Vitro Models for Simulating Drug Precipitation</i> | 58 |
| 2.1.4. | <i>What is the Benefit of Coupling Dissolution Results with PBPK Models? A Statement of How to Establish IVISIVC</i> | 63 |
| 2.2. | PBPK Models to Predict the Pharmacokinetics of Poorly Soluble Drugs – A Guide to Appropriate Model Selection | 68 |
| 2.2.1. | <i>From 2001 to Now – The Evolution of the STELLA® PBPK Model</i> | 68 |
| 2.2.2. | <i>A Comparison of the STELLA®-Based Model with Commercial PBPK Models: Advantages and Limitations</i> | 74 |
| 2.2.3. | <i>Which PBPK Model Covers My Situation Best?</i> | 79 |
| 2.2.4. | <i>Regulatory Applications of PBPK Modeling</i> | 82 |
| 3. | Summary and Outlook | 86 |
| 4. | German Summary (Deutsche Zusammenfassung) | 89 |
| 5. | References | 94 |
| 6. | Publications | 118 |
| 6.1. | Publication List | 118 |
| 6.1.1. | <i>Peer-Reviewed Papers</i> | 118 |
| 6.1.2. | <i>Review Articles</i> | 118 |
| 6.1.3. | <i>Book Chapter</i> | 118 |
| 6.1.4. | <i>Poster Presentations</i> | 119 |



| | | |
|--------|--|------------|
| 6.2. | Personal Contributions to Peer-Reviewed Papers and Book Chapter | 121 |
| 6.3. | Original Publications (Peer-Reviewed Papers and Book Chapter) | 122 |
| 6.3.1. | <i>Biorelevant in Vitro Dissolution Testing of Products Containing Micronized or Nanosized Fenofibrate with a View to Predicting Plasma Profiles</i> | 122 |
| 6.3.2. | <i>Predicting the Oral Absorption of a Poorly Soluble, Poorly Permeable Weak Base using Biorelevant Dissolution and Transfer Model Tests Coupled with a Physiologically Based Pharmacokinetic Model</i> | 130 |
| 6.3.3. | <i>Utilizing in Vitro and PBPK Tools to Link ADME Characteristics to Plasma Profiles: Case Example Nifedipine Immediate Release Formulation</i> | 142 |
| 6.3.4. | <i>In Vitro – in Silico Tools to Predict Pharmacokinetics of Poorly Soluble Drug Compounds. Chapter 12 in: Predictive ADMET: Integrated Approaches in Drug Discovery and Development</i> | 157 |
| 7. | Curriculum Vitae | 195 |
| 8. | Academic Teachers | 201 |